Determines overall survival in patients treated with VEGF–targeted therapy.
The Heng score (Database Consortium Model) has theoretical advantages over some other scores:
- A successful validation study.
- Focus on those receiving modern treatments in common practice.
While the score has not been shown to be accurate in any prospective study it may be among the most likely to correctly predict survival categories.
We are unaware of validated management algorithms using the score.
The Heng score is relevant exclusively to mRCC patients undergoing VEGF therapy.